The Latest Analyst Ratings for Apellis Pharmaceuticals
Portfolio Pulse from Benzinga Insights
In the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) received 7 bullish, 1 somewhat bullish, and 3 indifferent analyst ratings. The average 12-month price target for APLS has increased by 17.24% to $102.91, with a high of $156 and a low of $67.
June 13, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Apellis Pharmaceuticals received mostly bullish analyst ratings in the last quarter, with an increased average 12-month price target of $102.91.
The majority of analyst ratings for Apellis Pharmaceuticals are bullish, indicating a positive outlook for the stock. The increased average 12-month price target of $102.91, up 17.24% from the previous target, suggests that analysts expect the stock to perform well in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100